- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06222554
Examining the Use of a Novel Immersive Motion Tracking Upper Extremity Exercise Program for Acute Hospitalized Patients
March 5, 2024 updated by: NYU Langone Health
Pilot/Feasibility Study Examining the Use of a Novel Immersive Motion Tracking Upper Extremity Exercise Program for Acute Hospitalized Patients
The objective of this study is to evaluate the feasibility of the MoveMend Health software program as an integrated supplement to traditional acute care/in-hospital occupational therapy for patients following liver and kidney transplants, as determined by recruitment rates, program completion, intervention adherence, safety incidence, and patient feedback on device/program performance.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gabrielle Berne
- Phone Number: (914) 960-5355
- Email: Gabrielle.berne@nyulangone.org
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- English speaking (software program is currently only available in English)
- Status post kidney or liver transplant this admission
- Physician orders for occupational therapy evaluation and treatment
- Orientation Log > 25
- Negative for delirium per the Confusion Assessment Method
Exclusion Criteria:
- Orthopedic or surgical precautions that limits shoulder range of motion beyond 90 degrees
- Upper extremity hemiplegia with inability to lift upper extremity against gravity
- Accommodation code of Intensive Care Unit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients Hospitalized following Kidney or Liver Transplant
Patients in the study will be introduced to the exercise software program and provided with a demonstration.
Measurements will be taken at baseline (post-operation) and at the final study visit.
Participants will remain in the study until the end of their hospital stay, typically no longer than 6 months post-operation.
|
Software-based therapeutic tool that offers gamified exercises and activities.
The device is designed for deployment on tablets.
The core purpose of the device is to augment patient engagement and participation in their own rehabilitation by providing additional therapeutic interventions between formal occupational therapy sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment Rate
Time Frame: Up to Month 6 Post-Operation
|
Calculated by dividing the number of participants enrolled by the total number of patients contacted or screened.
|
Up to Month 6 Post-Operation
|
Percentage of Participants who Complete Exercise Program
Time Frame: Up to Month 6 Post-Operation
|
Percentage of enrolled participants who complete the interventional program.
|
Up to Month 6 Post-Operation
|
Percentage of Participants who Adhere to Intervention
Time Frame: Up to Month 6 Post-Operation
|
Measured by session duration and frequency, as recorded by the device.
Participants will be classified as "adhering" or "not adhering."
|
Up to Month 6 Post-Operation
|
Number of Adverse Events
Time Frame: Up to Month 6 Post-Operation
|
Measured using data from participant's electronic medical record.
|
Up to Month 6 Post-Operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Activity Measure for Post-Acute Care (AMPAC) Score
Time Frame: Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
12-item assessment of basic mobility of inpatients.
Each item is rated on a Likert scale from 1-4.
The raw score is the sum of responses, which is converted to a T-score.
The total score is a T-score ranging from 0 to 100; higher scores indicate greater mobility.
|
Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
Change in Grip Strength
Time Frame: Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
Measured as the percentage change in grip strength between the baseline assessment and the final assessment at discharge.
|
Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
Upper Extremity Range of Motion (ROM) Change
Time Frame: Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
Measured as the change in degrees of ROM at the shoulder and elbow as measured by a goniometer from baseline to discharge.
|
Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score
Time Frame: Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis.
There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state.
Overall scores range from 0 to 1, with low scores representing a higher level of dysfunction.
|
Baseline, End of Hospital Stay (typically no more than 6 months post-operation)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steve Vanlew, NYU Langone Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
April 17, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
January 16, 2024
First Submitted That Met QC Criteria
January 16, 2024
First Posted (Actual)
January 24, 2024
Study Record Updates
Last Update Posted (Estimated)
March 6, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 23-01384
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health.
Requests may be directed to: Gabrielle Berne, Gabrielle.berne@nyulangone.org.
The protocol and statistical analysis plan will be made available on Clinicaltrials.gov
only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data will be granted access upon reasonable request.
Requests should be directed to Gabrielle.berne@nyulangone.org.
To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
-
Memorial Bahçelievler HospitalCompletedLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Transplant; Complications | Liver Transplant Rejection | Organ Transplant Failure or Rejection | Liver Transplant FailureTurkey
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedLiver Transplant | Kidney TransplantUnited States, Singapore
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
Paragonix TechnologiesEnrolling by invitationLiver Diseases | Liver Transplant Disorder | Liver Dysfunction | Liver Transplant RejectionUnited States
-
PilloxaTerminatedLiver Transplant; Complications | Kidney Transplant; ComplicationsSweden
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...CompletedLiver Transplant Recipient | Living Donor (of the Respective Liver Transplant Recipient)United States
Clinical Trials on MoveMend Health
-
Florida State UniversityUniversity of North Carolina, Chapel Hill; University of GeorgiaEnrolling by invitationCardiovascular Disease Risk ReductionUnited States
-
Universiti Putra MalaysiaRecruitingNeck Pain | Cervical Spondylosis | Neck DisorderChina
-
University of WashingtonNational Institute on Aging (NIA)RecruitingOsteo Arthritis KneeUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI)CompletedCervical Cancer | Breast CancerUnited States
-
Boston Children's HospitalCenters for Disease Control and PreventionCompletedInfluenzaUnited States
-
M.D. Anderson Cancer CenterDuncan Family Institute (DFI) Seed Funding ProgramRecruiting
-
Norwegian School of Sport SciencesNational Dairy CouncilCompletedDepression | Exercise Addiction | Perfectionism | Binge Eating | Body Image | Eating Disorder | Resting Metabolic Rate | Dietary Deficiency | Bone Mineral Density, Low, Susceptibility to | Exercise-Related Amenorrhea | Dietary AmenorrheaNorway
-
University of Alabama at BirminghamAmerican Heart Association; ConnectionHealth; Memora HealthRecruitingPregnancy | Disparities | InfantsUnited States
-
Ayşegül AkcaThe Scientific and Technological Research Council of TurkeyCompleted
-
Paijat-Hame Hospital DistrictPfizer; Tampere University; Sitra, the Finnish Innovation FundUnknownHeart Failure | Coronary Disease | Diabetes Mellitus, Type 2Finland